The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study

Juferdy Kurniawan, Rino A Gani, Samsuridjal Djauzi, Fera Ibrahim, Kuntjoro Harimurti, nafrialdi nafrialdi, Suzanna Imannuel


Background: HIV infection in HCV-infected patients accelerates disease progression and reduces the success rate of Peg-IFN/RBV treatment. HCV mutation in NS5A-ISDR/PKR-BD region improved the outcome in HCV monoinfection treated with Peg-IFN/RBV. SNP-IL28B polymorphism is predicted to have an effect on HCV quasispecies evolution. However, the role of NS5A mutation and SNP IL-28B in HIV-HCV coinfection is still unclear. The aim of the study is to determine the role of HCV NS5A-ISDR/PKR-BD mutation and SNP IL-28 polymorphism on the successfulness of Peg-IFN/RBV therapy in HCV-HIV coinfection. Methods: prospective cohort was performed in this study. Plasma sample were obtained from 30 and 8 patients with HCV-HIV coinfection and HCV monoinfection, respectively. PCR nucleotide sequencing was performed after RNA virus extraction and cDNA synthesis. Protein secondary structure and prediction of mutation function were analyzed using PredictProtein (PP) program. Results: sixteen HCV-HIV coinfected patients and none from eight HCV patients achieved sustained virological response (SVR). ≥1 non-neutral mutation was found in 24/30 HCV-HIV coinfection and more frequent in SVR group (14 patients). ≥1 non-neutral mutation were found statistically significant for overall SVR achievement (p<0.05) in all patients regardless of coinfection or monoinfection status. Of the 27 HCV-HIV coinfected patients with CC-gene, 21 subjects had non-neutral mutation. The structure which was expected as NS5A binding site structure was different from consensus (wild type) in SVR group, while the structure was similar to consensus in non-SVR group. Conclusion: having ≥1 non-neutral mutation was associated with SVR achievement in Peg-IFN/RBV therapy, regardless of monoinfection and coinfection status.


NS5A-ISDR/PKR-BD; SNP IL-28B; HCV-HIV coinfection; nonneutral mutation; SVR


Taylor LE, Swan T, Mayer KH. HIV Coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis. 2012;55:33-42.

Deng LP, Gui XE, Zhang YX, Gao SC, Yang RR. Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. World J Gastroenterol. 2009;15(8):996-1003.

Center for Disease Control and Prevention. HIV and viral hepatitis factsheets. 2017.

Yunihastuti E, Djoerban Z, Djauzi S, Gani RA. Coinfection of hepatitis B and C among HIV infected patients: a database of HIV Clinic Cipto Mangunkusumo Hospital Jakarta 2004-2009. 2011.

McCaughan GW, Omata M, Amarpurkar D, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007;22(5):615-33.

Tural C, Galeras JA, Planas R, et al. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients. Antivir Ther. 2008;13(8):1047-55.

Enomoto H, Nishiguchi S. Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C. World J Hepatol. 2015;7(26):2681-7.

El-Shamy A, Shoji I, Saito T, et al. Sequence heterogenity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy. Microbiol Immunol. 2011;55(6):418-26.

DeRueda PM, Casado J, Paton R, et al. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR and NS5A-V3 of hepatitis C virus genotypr 1 and their relationships to pegylated interferon-ribavirin treatment responses. J Virol. 2008;82(13):6644-53.

Zeuzem S, Lee JH, Kurt RW. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology. 1997;25(3):740-4.

Hofgartner WT, Polyak SJ, Sullivan DG, Carithers RL, Gretch DR. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J Med Virol. 1997;53(2):118-26.

Ng PC, Henikoff S. Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet. 2006;7:61-80.

Bromberg Y, Rost B. SNAP: predict effect of non-synonymous polymorphisms on function. Nucleic Acids Res. 2007;35(11):3823-35.

Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(762):399-401.

Lusida MI, Nagano-Fujii M, Nidom CM, et al. Correlation between mutations in the interferon sensitivity-determining region of NS5A protein and viral load of hepatitis C virus subtypes 1b, 1c, and 2a. J Clin Microbiol. 2001;39(11):3858-64.

Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-76.

Chen W, Liao B, Hu F, et al. Changing epidemiology of hepatitis C virus genotype among patients with human immunodeficiency virus/hepatitis C virus co-infection in China. PLoS One. 2016;11(9).

Forde KA, Bhattacharya D. Treatment of hepatitis C virus (HCV) genotype 1 disease. Curr Treat Options Infect Dis. 2017;9(2):262-726.

Abdel-Hameed EA, Rouster SD, Boyce CL, et al. Ultra-deep genomic sequencing of HCV NS5A resistance-associated substitutions in HCV/HIV coinfected patients. Dig Dis Sci. 2018;63(3):645-52.

Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2013;11(6):362-71.

Lin W, Weinberg EM, Tai AW, et al. HIV increases HCV replication in a TGF-β1-dependent manner. Gastroenterology. 2008;134(3):803-11.

Laskus T, Radkowski M, Jablonska J, et al. Human immunodeficiency virus facilitates infection/replication of hepatitis C virus in native human macrophages. Blood. 2004;103(10):3854-9.

Sanjuan R, Domingo-Calap P. Mechanisms of viral mutation. Cell Mol Life Sci. 2016;73(23):4433-48.

Duffy S. Why are RNA virus mutation rates so damn high? PLoS Biol. 2018;16(8):1-6.

Sugiyama R, Murayama A, Nitta S, et al. Interferon sensitivity-determining region of hepatitis C virus influences virus production and interferon signalling. Oncotarget. 2018;9(5):5627-40.

Halfon P, Bourliere M, Ouzan D, et al. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C genotype 1 virus. Eur J Gastroenterol Hepatol. 2011;23(10):931-5.

Khubaib B, Saleem S, Idrees M, Afzal S, Wasim M. The genotype CC of IL-28 SNP rs127989860 is significantly associated with a sustained virological response in chronic HCV-infected Pakistani patients. J Dig Dis. 2015;16(5):293-8.

Yuan H, Adams-Huet B, Petersen T, Attar N, Lee W, Jain M. A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy. J Med Virol. 2012;84(12):1913-9.

Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010;139(2):499-509.

Full Text: PDF


  • There are currently no refbacks.